These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 36544769)

  • 41. First-line treatment options for advanced non-small cell lung cancer patients with PD-L1 ≥ 50%: a systematic review and network meta-analysis.
    He M; Zheng T; Zhang X; Peng Y; Jiang X; Huang Y; Tan B; Yang Z
    Cancer Immunol Immunother; 2022 Jun; 71(6):1345-1355. PubMed ID: 34657171
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The benefit and risk of PD-1/PD-L1 inhibitors plus anti-angiogenic agents as second or later-line treatment for patients with advanced non-small-cell lung cancer: a systematic review and single-arm meta-analysis of prospective clinical trials.
    Chen S; Mo W; Jiang W; Zhou S; Gan H; Yu Q
    Front Immunol; 2023; 14():1218258. PubMed ID: 37614237
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparative analysis of immune checkpoint inhibitors and chemotherapy in the treatment of advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials.
    Khan M; Lin J; Liao G; Tian Y; Liang Y; Li R; Liu M; Yuan Y
    Medicine (Baltimore); 2018 Aug; 97(33):e11936. PubMed ID: 30113497
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immunotherapy combined with chemotherapy versus chemotherapy alone as the first-line treatment of PD-L1-negative and driver-gene-negative advanced nonsquamous non-small-cell lung cancer: An updated systematic review and meta-analysis.
    Chai Y; Wu X; Zou Y; Zhang X; Bai H; Dong M; Duan J
    Thorac Cancer; 2022 Nov; 13(22):3124-3132. PubMed ID: 36168110
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy and Safety of Programmed Death 1/Programmed Death-Ligand 1 Plus Cytotoxic T-Lymphocyte-Associated Antigen 4 Inhibitors for Advanced or Metastatic Non-Small Cell Lung Cancer: A Meta-analysis Based on Randomized Controlled Trials.
    Ren W; Fang Y; He Y; Ren Y; Wang M; Xu A; Ruan J; Tao Q
    Ther Drug Monit; 2024 Aug; 46(4):422-433. PubMed ID: 38840327
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prognostic significance of programmed cell death ligand 1 blood markers in non-small cell lung cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
    Zhang N; Chang J; Liu P; Tian X; Yu J
    Front Immunol; 2024; 15():1400262. PubMed ID: 38915398
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Predictive effect of PD-L1 expression for immune checkpoint inhibitor (PD-1/PD-L1 inhibitors) treatment for non-small cell lung cancer: A meta-analysis.
    Zhang B; Liu Y; Zhou S; Jiang H; Zhu K; Wang R
    Int Immunopharmacol; 2020 Mar; 80():106214. PubMed ID: 31982822
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy of PD-1/PD-L1 inhibitors in patients with advanced non-small cell lung cancer: A meta-analysis of randomized clinical trials.
    Peng TR; Wu TW
    Thorac Cancer; 2019 May; 10(5):1176-1181. PubMed ID: 30969033
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and safety of first-line immunotherapy plus chemotherapy in treating patients with extensive-stage small cell lung cancer: a Bayesian network meta-analysis.
    Zhang T; Li W; Diwu D; Chen L; Chen X; Wang H
    Front Immunol; 2023; 14():1197044. PubMed ID: 37435087
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy of PD-1/L1 inhibitors in brain metastases of non-small-cell lung cancer: pooled analysis from seven randomized controlled trials.
    Li W; Jiang J; Huang L; Long F
    Future Oncol; 2022 Jan; 18(3):403-412. PubMed ID: 34787500
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical benefits of PD-1 inhibitors in specific subgroups of patients with advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis of phase 3 randomized clinical trials.
    Lu Y; Wang W; Wang F
    Front Immunol; 2023; 14():1171671. PubMed ID: 37205107
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparative efficacy of chemoimmunotherapy versus immunotherapy for advanced non-small cell lung cancer: A network meta-analysis of randomized trials.
    Pathak R; De Lima Lopes G; Yu H; Aryal MR; Ji W; Frumento KS; Wallis CJD; Klaassen Z; Park HS; Goldberg SB
    Cancer; 2021 Mar; 127(5):709-719. PubMed ID: 33119177
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Network meta-analysis of first-line immune checkpoint inhibitor therapy in advanced non-squamous non-small cell lung cancer patients with PD-L1 expression ≥ 50.
    Chen W; Chen J; Zhang L; Cheng S; Yu J
    BMC Cancer; 2023 Aug; 23(1):791. PubMed ID: 37612622
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy and Safety of Programmed Cell Death 1 Inhibitor Monotherapy Versus Chemotherapy as Second-Line Treatment for Advanced Esophageal Cancer: A Meta-analysis and Systematic Review.
    Yang YL; Li ZQ; Wang QL; Gu JJ; Fang XJ; Huang GH
    Clin Ther; 2021 Nov; 43(11):1997-2012. PubMed ID: 34794831
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinico-characteristics of patients which correlated with preferable treatment outcomes in immunotherapy for advanced hepatocellular carcinoma: a systematic review and meta-analysis.
    Wang Y; Lau W; Li Y; Tian Y; Lei Y; Wang J; Xia F
    Int J Surg; 2023 Nov; 109(11):3590-3601. PubMed ID: 37598406
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy and safety of PD-1/PD-L1 inhibitors plus chemotherapy for triple-negative breast cancer: a systematic review and meta-analysis.
    Cui W; Luo Q; Sun SL; Xu JL; Gu H
    Recenti Prog Med; 2022 Dec; 113(12):722-732. PubMed ID: 36420848
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Association between CD8+ tumor-infiltrating lymphocytes and prognosis of non-small cell lung cancer patients treated with PD-1/PD-L1 inhibitors: a systematic review and meta-analysis.
    Zheng QM; Li YY; Wang YP; Li GX; Zhao MM; Sun ZG
    Expert Rev Anticancer Ther; 2023 Jun; 23(6):643-659. PubMed ID: 37114477
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical benefit analysis of PD-1 inhibitors in patients with advanced, recurrent or metastatic cervical cancer: a meta-analysis and systematic review.
    Wang YZ; Wang JS; Du J; Tang XL; Xiao JP
    Front Immunol; 2024; 15():1305810. PubMed ID: 38327524
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prognostic significance of blood-based PD-L1 analysis in patients with non-small cell lung cancer undergoing immune checkpoint inhibitor therapy: a systematic review and meta-analysis.
    Cui Q; Li W; Wang D; Wang S; Yu J
    World J Surg Oncol; 2023 Oct; 21(1):318. PubMed ID: 37821941
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy and safety of anlotinib combined with PD-1/PD-L1 inhibitors as second-line and subsequent therapy in advanced small-cell lung cancer.
    Yu L; Xu J; Qiao R; Han B; Zhong H; Zhong R
    Cancer Med; 2023 Mar; 12(5):5372-5383. PubMed ID: 36250532
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.